ZEVRA THERAPEUTICS, INC. 10-Q — AI Bull & Bear Analysis

Zevra's Q1 2026 filing presents a company at a critical inflection point, having traded financial risk for operational execution risk. The total repayment of its term loans and the massive cash infusion from the PRV sale and Commave settlement have provided a vital runway, effectively removing the immediate threat of insolvency. However, the transition to a sustainable commercial model is still in its early stages, as the company struggles to align its high SG&A spend with its current revenue scale. Investors must now weigh the genuine growth of MIPLYFFA against the lack of recurring profitability. While the balance sheet is clean, the operational engine is still heavily reliant on a very small patient population and a single distribution channel. The next twelve months will be decisive, as the company seeks to prove that its revenue growth can outpace its operating expenses without the aid of asset sales.